Ballroom TUV, Hyatt Regency | Supported By: Boehringer Ingelheim

---

Program Description

Please join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium where they will provide a comprehensive review of JASCAYD® (nerandomilast) tablets, indicated for adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). During this event, Dr. Hamblin and Dr. Scholand will discuss the safety and efficacy data of JASCAYD, the details of the pivotal phase III trial that led to its approval, and the importance of identifying appropriate patients for treatment.

INDICATIONS

JASCAYD is indicated for:

• the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.
• the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions with an incidence of ≥5% in patients treated with JASCAYD were diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness.

DRUG INTERACTIONS

Effects of Other Drugs on JASCAYD

• Strong CYP3A Inhibitors: Reduce the dosage of JASCAYD to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with a strong CYP3A inhibitor increases exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions.
• Moderate or Strong CYP3A Inducers: Avoid use of JASCAYD with strong or moderate CYP3A inducers. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with moderate or strong CYP3A inducers is expected to decrease exposure of nerandomilast, which may decrease the efficacy of JASCAYD.
• Pirfenidone: Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with pirfenidone. Do not reduce the dosage to 9 mg twice daily. Concomitant use of JASCAYD with pirfenidone decreases exposure of nerandomilast in patients with IPF. When JASCAYD was used concomitantly with pirfenidone in patients with IPF in FIBRONEER-IPF, efficacy was not observed with the JASCAYD 9 mg twice daily dosage.

USE IN SPECIFIC POPULATIONS

• Pregnancy: Advise pregnant women and females of reproductive potential of the potential risk of fetal loss.
• Renal Impairment: Use of JASCAYD is not recommended in patients with end stage renal disease (eGFR <15 mL/minute/1.73 m2).
• Hepatic Impairment: Use of JASCAYD is not recommended in patients with severe (Child-Pugh Class C) hepatic impairment.

CL-JS-100016 12.19.2025

Click Here for Full Prescribing Information, include Patient Information.

Speakers

Presenter: Mark Hamblin, MD, FCCP
University of Kansas Medical Center
Pulmonary, Critical Care, and Sleep Medicine

University of Kansas Medical Center
ILD and Rare Lung Disease Program
Director
Kansas City, Kansas

Mary Beth Scholand, MD, FCCP
Director, Interstitial Lung Disease Clinic
University of Utah Health
Salt Lake City, UT